Scotiabank Initiates Coverage On Beam Therapeutics with Sector Perform Rating, Announces Price Target of $24
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on Beam Therapeutics with a Sector Perform rating and set a price target of $24.
October 16, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Scotiabank has initiated coverage on Beam Therapeutics with a Sector Perform rating and a price target of $24, indicating a neutral outlook.
The Sector Perform rating suggests that Beam Therapeutics is expected to perform in line with the sector. The price target of $24 provides a specific valuation benchmark, which is crucial for investors. The neutral rating implies no significant short-term price movement is expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100